Gunnar Gårdemyr has been named the new CEO of Norwegian company Targovax, effective Jan. 12, 2015.
Gårdemyr has spent 30 years in the international pharmaceutical and biotech industries and brings experience in management, business development, mergers and acquisitions, global marketing and commercial strategy to Targovax. Currently he is the corporate advisor for Acino Pharma in Basel, Switzerland.
Jónas Einarsson, Chairman of Targovax, said in a prepared statement, “We are delighted to welcome Gunnar Gårdemyr to Targovax. Our ability to attract an experienced industry executive with Gunnar’s track record and knowledge reflects Targovax` potential. His leadership will accelerate the company’s further development.”
Located in Lysaker, Targovax was established in October 2010 to develop immunotherapy in the form of therapeutic cancer vaccines based on research at the Norwegian Radium Hospital and Norsk Hydro.